Repros Therapeutics (RPRX) Tops Q3 EPS by 2c

Repros Therapeutics (NASDAQ: RPRX) reported Q3 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29).

For earnings history and earnings-related data on Repros Therapeutics (RPRX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating